Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms

Author:

Larkin James R.1ORCID,Anthony Susan2,Johanssen Vanessa A.1ORCID,Yeo Tianrong345ORCID,Sealey Megan3,Yates Abi G.3,Smith Claire Friedemann6ORCID,Claridge Timothy D.W.7ORCID,Nicholson Brian D.6,Moreland Julie-Ann2ORCID,Gleeson Fergus12,Sibson Nicola R.1ORCID,Anthony Daniel C.3ORCID,Probert Fay37

Affiliation:

1. 1Medical Research Council Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, United Kingdom.

2. 2Department of Radiology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.

3. 3Department of Pharmacology, Medical Sciences Division, University of Oxford, Oxford, United Kingdom.

4. 4Department of Neurology, National Neuroscience Institute, Singapore.

5. 5Duke-NUS Medical School, Singapore.

6. 6Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.

7. 7Department of Chemistry, University of Oxford, Oxford, United Kingdom.

Abstract

Abstract Purpose: Early diagnosis of cancer is critical for improving patient outcomes, but cancers may be hard to diagnose if patients present with nonspecific signs and symptoms. We have previously shown that nuclear magnetic resonance (NMR) metabolomics analysis can detect cancer in animal models and distinguish between differing metastatic disease burdens. Here, we hypothesized that biomarkers within the blood metabolome could identify cancers within a mixed population of patients referred from primary care with nonspecific symptoms, the so-called “low-risk, but not no-risk” patient group, as well as distinguishing between those with and without metastatic disease. Experimental Design: Patients (n = 304 comprising modeling, n = 192, and test, n = 92) were recruited from 2017 to 2018 from the Oxfordshire Suspected CANcer (SCAN) pathway, a multidisciplinary diagnostic center (MDC) referral pathway for patients with nonspecific signs and symptoms. Blood was collected and analyzed by NMR metabolomics. Orthogonal partial least squares discriminatory analysis (OPLS-DA) models separated patients, based upon diagnoses received from the MDC assessment, within 62 days of initial appointment. Results: Area under the ROC curve for identifying patients with solid tumors in the independent test set was 0.83 [95% confidence interval (CI): 0.72–0.95]. Maximum sensitivity and specificity were 94% (95% CI: 73–99) and 82% (95% CI: 75–87), respectively. We could also identify patients with metastatic disease in the cohort of patients with cancer with sensitivity and specificity of 94% (95% CI: 72–99) and 88% (95% CI: 53–98), respectively. Conclusions: For a mixed group of patients referred from primary care with nonspecific signs and symptoms, NMR-based metabolomics can assist their diagnosis, and may differentiate both those with malignancies and those with and without metastatic disease. See related commentary by Van Tine and Lyssiotis, p. 1477

Funder

CRUK

CRUK EPSRC Cancer Imaging Centre in Oxford

Diagnostics Co-operative

Oxford-Wellcome Institutional Strategic Support Fund

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 33 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3